Renalytix Plc (RNLXY) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the filing for Q1 FY2025, filed Nov 19, 2024. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RNLXY SEC filings page.
Renalytix Plc (RNLXY) reported $2.4M in revenue over the twelve months to Sep 30, 2024, down 18.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
FY2024’s sales contraction exposed weak gross economics, while development spending and liabilities remained far larger than the operating base.
In FY2024, revenue fell32.7% while gross profit fell78.3% . Because SG&A and R&D also fell31.1% and35.0% , unit economics deteriorated faster than overhead was reduced.
R&D was
Liabilities reached
Financial Health Signals
We do not publish a peer-relative financial health score for Renalytix Plc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Renalytix Plc scores -48.09, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $211.8M against total assets of $8.0M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Renalytix Plc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.
Renalytix Plc reported a net loss of $33.5M while operations used $30.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Renalytix Plc generated $522K in revenue in Q1 2025. This represents an increase of 13.7% from the same quarter a year earlier. Against the prior quarter it is down 10.9%.
Renalytix Plc's EBITDA was -$4.0M in Q1 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Renalytix Plc reported a net loss of $4.7M in Q1 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Renalytix Plc held $909K in cash against $4.1M in long-term debt as of Q1 2025.
Not reported for Q1 2025.
Not reported for Q1 2025.
Margins & Returns
Renalytix Plc's gross margin was 19.2% in Q1 2025, indicating the percentage of revenue retained after direct costs. This is up 28.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.0 percentage points.
Not shown for Q1 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q1 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q1 2025.
Capital Allocation
Renalytix Plc invested $921K in research and development in Q1 2025. This represents a decrease of 67.0% from the same quarter a year earlier. Against the prior quarter it is down 13.3%.
Not reported for Q1 2025.
Not reported for Q1 2025.
RNLXY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing |
|---|---|---|---|---|---|---|---|---|
| Revenue | $522K+13.7% | $586K+13.1% | $535K-26.1% | $709K-40.5% | $459K-52.6% | $518K-37.7% | $724K-10.8% | $1.2M+41.1% |
| Cost of Revenue | $422K-15.9% | $550K-18.3% | $601K-0.3% | $480K-32.5% | $502K-27.9% | $673K-2.7% | $603K-12.0% | $711K+44.5% |
| Gross Profit | $100Kn/m | $36Kn/m | -$66K-154.5% | $229K-52.4% | -$43K-115.8% | -$155K-211.5% | $121K-4.7% | $481K+36.3% |
| R&D Expenses | $921K-67.0% | $1.1M-67.5% | $2.2M-43.8% | $3.2M-3.0% | $2.8M-25.8% | $3.3M+24.5% | $3.9M+1.4% | $3.3M-19.5% |
| SG&A Expenses | $3.3M-46.0% | $4.5M-30.9% | $3.9M-45.7% | $5.3M-21.6% | $6.1M-26.6% | $6.5M-38.1% | $7.1M-34.4% | $6.8M-32.4% |
| Operating Income | -$4.1Mn/m | -$5.5Mn/m | -$6.6Mn/m | -$8.6Mn/m | -$8.9Mn/m | -$9.9Mn/m | -$10.9Mn/m | -$9.6Mn/m |
| EBITDA | -$4.0Mn/m | -$5.5Mn/m | -$6.5Mn/m | -$8.5Mn/m | -$8.8Mn/m | -$9.8Mn/m | -$10.8Mn/m | -$9.5Mn/m |
| Income Tax | $2Kn/m | $0-100.0% | $0n/m | $4Kn/m | $0-100.0% | $2K-92.0% | -$1Kn/m | $0n/m |
| Net Income | -$4.7Mn/m | -$7.1Mn/m | -$7.7Mn/m | -$8.5Mn/m | -$10.2Mn/m | -$11.1Mn/m | -$12.1Mn/m | -$10.4Mn/m |
| EPS (Basic) | -$0.04 | -$0.04 | -$0.08n/m | -$0.09n/m | -$0.11n/m | -$0.11 | -$0.14n/m | -$0.14n/m |
| EPS (Diluted) | -$0.04 | -$0.04 | -$0.08n/m | -$0.09n/m | -$0.11n/m | -$0.11 | -$0.14n/m | -$0.14n/m |
| Diluted Shares (Avg) | 106M | N/A | 98M+14.1% | 97M+29.9% | 95M+26.7% | N/A | 86M+18.3% | 75M+3.6% |
Not reported in any period shown, so not listed: Interest Expense.
RNLXY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.8M-75.5% | $8.0M-74.0% | $8.8M-78.0% | $11.3M-63.2% | $19.5M-49.5% | $30.6M-38.8% | $39.8M-10.5% | $30.7M-43.6% |
| Current Assets | $2.9M-82.5% | $6.1M-77.2% | $6.3M-82.3% | $8.3M-69.0% | $16.5M-52.2% | $26.9M-39.9% | $35.7M-4.2% | $26.6M-40.1% |
| Cash & Equivalents | $909K-93.5% | $4.7M-81.0% | $4.7M-85.8% | $5.6M-76.4% | $13.9M-55.2% | $24.7M-40.3% | $33.0M+2.1% | $23.8M-40.4% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Accounts Receivable | $902K-11.0% | $722K-7.0% | $554K-25.8% | $1.4M+67.1% | $1.0M-17.1% | $776K-13.9% | $747K-26.0% | $820K-0.4% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $16.1M-23.4% | $15.8M-33.1% | $19.9M-8.4% | $19.2M-11.7% | $21.0M+5.8% | $23.7M+21.6% | $21.7M+44.2% | $21.8M+154.5% |
| Current Liabilities | $12.0M-20.8% | $11.5M-28.8% | $15.0M+2.1% | $13.9M-2.6% | $15.2M+13.8% | $16.1M+37.0% | $14.7M-2.3% | $14.3M+67.3% |
| Non-Current Liabilities | $4.1M-30.0% | $4.3M-42.5% | $4.9M-30.3% | $5.3M-29.1% | $5.9M-10.4% | $7.5M-2.0% | $7.0M+50050.0% | $7.5M+49820.0% |
| Long-Term Debt | $4.1M-29.9% | $4.3M-42.1% | $4.9M-29.6% | $5.3M-28.1% | $5.8M-8.7% | $7.5M-2.6% | $7.0M | $7.4M |
| Total Equity | -$11.3Mn/m | -$7.9M-212.7% | -$11.1M-161.4% | -$8.0M-189.5% | -$1.5M-107.9% | $7.0M-77.2% | $18.1M-38.5% | $8.9M-80.6% |
| Retained Earnings | -$216.5Mn/m | -$211.8Mn/m | -$204.7Mn/m | -$197.0Mn/m | -$188.5Mn/m | -$178.3Mn/m | -$167.2Mn/m | -$155.1Mn/m |
Not reported in any period shown, so not listed: Inventory, Goodwill.
RNLXY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.8Mn/m | -$7.8Mn/m | -$4.9Mn/m | -$7.9Mn/m | -$9.5Mn/m | -$8.6Mn/m | -$10.1Mn/m | -$8.2Mn/m |
| Depreciation & Amortization | $60K-52.8% | $60K-50.0% | $69K-46.9% | $108K-15.6% | $127K-2.3% | $120K-11.1% | $130K+1.6% | $128K+19.6% |
| Stock-Based Compensation | $254K-51.4% | N/A | $385K-50.0% | $385K-52.8% | $523K-31.8% | N/A | $770K-16.6% | $815K-10.7% |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $0-100.0% |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$8.6M | -$10.1Mn/m | -$8.2Mn/m |
| Investing Cash Flow | $23Kn/m | -$1K-101.7% | -$3K-160.0% | $0n/m | $0n/m | $59K-1.7% | $5Kn/m | -$64Kn/m |
| Financing Cash Flow | $0n/m | $7.8Mn/m | $4.0M-77.6% | -$507Kn/m | -$1.1Mn/m | -$98K-100.4% | $18.0Mn/m | -$588K-629.7% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
RNLXY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 19.2%+28.5pp | 6.1%+36.1pp | -12.3%-29.0pp | 32.3%-8.1pp | -9.4%-37.5pp | -29.9%-46.7pp | 16.7%+1.1pp | 40.4%-1.4pp |
| Operating Margin | -784.1% | -942.8% | -1224.9% | -1218.8% | -1936.6% | -1917.8% | -1507.9% | -809.4% |
| Net Margin | -905.7% | -1207.2% | -1447.3% | -1196.8% | -2212.2% | -2143.6% | -1672.1% | -876.2% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | -159.4%-142.5pp | -66.9%-16.9pp | -117.5%-84.1pp |
| Return on Assets | -98.6%-46.6pp | -88.7%-52.5pp | -88.3%-57.9pp | -75.3%-41.2pp | -52.0%-21.1pp | -36.3%-26.0pp | -30.4%+2.6pp | -34.1%-5.9pp |
| Current Ratio | 0.24-0.8x | 0.53-1.1x | 0.42-2.0x | 0.59-1.3x | 1.09-1.5x | 1.67-2.1x | 2.430.0x | 1.86-3.3x |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | 1.07+0.8x | 0.38 | 0.83 |
| Liabilities-to-Equity | N/A | N/A | N/A | N/A | N/A | 3.40+2.8x | 1.20+0.7x | 2.45+2.3x |
| Asset Turnover | 0.11+0.1x | 0.07+0.1x | 0.060.0x | 0.060.0x | 0.020.0x | 0.020.0x | 0.020.0x | 0.040.0x |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -1666.6% | -1395.2% | -690.6% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$7.9M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.53), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Renalytix Plc RNLXY | FY2024 | $2.3M | -$33.5M | N/A | $49.6M | — |
| Vaso Corporation VASO | FY2025 | $89.1M | $1.6M | 1.8% | $49.8M | — |
| CareView Communs Inc CRVW | FY2025 | $9.0M | -$3.2M | -35.5% | $17.7M | — |
| Pharm-Bio Serv Inc PBSV | FY2025 | $9.0M | -$100K | -1.1% | $11.5M | — |
Where Renalytix Plc Ranks
Frequently Asked Questions
Renalytix Plc (RNLXY) reported $2.3M in total revenue for fiscal year 2024. This represents a -32.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Renalytix Plc (RNLXY) revenue declined by 32.7% year-over-year, from $3.4M to $2.3M in fiscal year 2024.
No, Renalytix Plc (RNLXY) reported a net loss of $28.0M over the trailing 12 months to September 30, 2024. In fiscal year 2024 it reported a net loss of $33.5M.
Renalytix Plc (RNLXY) had EBITDA of -$29.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2024, Renalytix Plc (RNLXY) had $4.7M in cash and equivalents against $4.3M in long-term debt.
Renalytix Plc (RNLXY) had a gross margin of 6.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
Renalytix Plc (RNLXY) recorded an outflow of $30.1M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
Renalytix Plc (RNLXY) had $8.0M in total assets as of fiscal year 2024, including both current and long-term assets.
Renalytix Plc (RNLXY) invested $9.3M in research and development during fiscal year 2024.
Renalytix Plc (RNLXY) had a current ratio of 0.53 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
Renalytix Plc (RNLXY) had a return on assets of -419.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
Renalytix Plc (RNLXY) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2024). The market capitalization is $49.6M as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Renalytix Plc (RNLXY) trades at 21.1x sales, its market capitalization divided by $2.4M revenue, trailing 12 months to September 30, 2024. The market capitalization is $49.6M as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2024, Renalytix Plc (RNLXY) held $4.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $30.1M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Renalytix Plc (RNLXY) has negative shareholder equity of -$7.9M as of fiscal year 2024, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Renalytix Plc (RNLXY) has an Altman Z-Score of -48.09, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Renalytix Plc (RNLXY) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Renalytix Plc (RNLXY) reported a net loss of $33.5M while operations used $30.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.